{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:35:15Z","timestamp":1794335715825,"version":"4.9.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.eclinm.2023.101953","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T12:40:29Z","timestamp":1680784829000},"page":"101953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017\u20132022"],"prefix":"10.1016","volume":"59","author":[{"given":"Chenghao","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanqiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4975-1095","authenticated-orcid":false,"given":"Jiaxuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songmei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2023.101953_bib1","series-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims","year":"2009"},{"issue":"2","key":"10.1016\/j.eclinm.2023.101953_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamainternmed.2016.7761","article-title":"Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints","volume":"177","author":"Rupp","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eclinm.2023.101953_bib3","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.eclinm.2023.101953_bib4","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.eclinm.2023.101953_bib5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/annonc\/mdx053","article-title":"Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015","volume":"28","author":"Vivot","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.101953_bib6","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdy449","article-title":"Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016","volume":"29","author":"Marandino","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.101953_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jamaoncol.2022.0864","article-title":"Association of quality-of-life outcomes in cancer drug trials with survival outcomes and drug class","volume":"8","author":"Samuel","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.101953_bib8","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1470-2045(18)30097-4","article-title":"Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada","volume":"19","author":"Kluetz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.101953_bib9","first-page":"278","article-title":"Patient-reported outcomes in cancer: a review of recent research and policy initiatives","volume":"57","author":"Lipscomb","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2023.101953_bib10","series-title":"Guidance for industry: core patient-reported outcomes in cancer clinical trials","year":"2021"},{"key":"10.1016\/j.eclinm.2023.101953_bib11","series-title":"Patient-focused drug development: collecting comprehensive and representative input","year":"2020"},{"key":"10.1016\/j.eclinm.2023.101953_bib12","series-title":"Patient-focused drug development: methods to identify what is important to patients","year":"2022"},{"key":"10.1016\/j.eclinm.2023.101953_bib13","series-title":"Patient-focused drug development: selecting, developing, or modifying fit-for purpose clinical outcome assessments","year":"2022"},{"issue":"2","key":"10.1016\/j.eclinm.2023.101953_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jval.2018.09.2842","article-title":"A\u00a0review of patient-reported outcomes labeling for oncology drugs approved by the FDA and the EMA (2012-2016)","volume":"22","author":"Gnanasakthy","year":"2019","journal-title":"Value Health"},{"issue":"16","key":"10.1016\/j.eclinm.2023.101953_bib15","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.2015.63.6480","article-title":"Patient-reported outcomes labeling for products approved by the office of hematology and oncology products of the US Food and Drug Administration (2010-2014)","volume":"34","author":"Gnanasakthy","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2023.101953_bib16","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S1470-2045(16)30510-1","article-title":"Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards","volume":"17","author":"Bottomley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.101953_bib17","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.101953_bib18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2023.101953_bib19","series-title":"Assessment of the use of patient experience data in regulatory decision-making","year":"2021"},{"issue":"32","key":"10.1016\/j.eclinm.2023.101953_bib20","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2007.11.3803","article-title":"Patient-reported outcomes supporting anticancer product approvals","volume":"25","author":"Rock","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"10125","key":"10.1016\/j.eclinm.2023.101953_bib21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101953_bib22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(18)30780-0","article-title":"Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study","volume":"20","author":"Downing","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2023.101953_bib23","series-title":"Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics","year":"2018"},{"issue":"6","key":"10.1016\/j.eclinm.2023.101953_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A\u00a025-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.101953_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol"},{"issue":"15_suppl","key":"10.1016\/j.eclinm.2023.101953_bib26","doi-asserted-by":"crossref","first-page":"e18702","DOI":"10.1200\/JCO.2018.36.15_suppl.e18702","article-title":"Exploring open-label bias in patient-reported outcome (PRO) emotional domain scores in cancer trials","volume":"36","author":"Chakravarti","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101953_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jnci\/djab177","article-title":"Impact of blinding on patient-reported outcome differences between treatment arms in cancer randomized controlled trials","volume":"114","author":"Efficace","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101953_bib28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.101953_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101953_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"7","key":"10.1016\/j.eclinm.2023.101953_bib31","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"32","key":"10.1016\/j.eclinm.2023.101953_bib32","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1200\/JCO.2007.12.2341","article-title":"Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative","volume":"25","author":"Garcia","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.101953_bib33","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/jnci\/djaa174","article-title":"Patient-reported outcomes in clinical trials leading to cancer immunotherapy drug approvals from 2011 to 2018: a systematic review","volume":"113","author":"Safa","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.eclinm.2023.101953_bib34","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jnci\/djz038","article-title":"Systematic evaluation of patient-reported outcome protocol content and reporting in cancer trials","volume":"111","author":"Kyte","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.eclinm.2023.101953_bib35","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S1470-2045(18)30418-2","article-title":"Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review","volume":"19","author":"Pe","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.101953_bib36","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1016\/S2352-3026(20)30292-1","article-title":"Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review","volume":"7","author":"Chakraborty","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.eclinm.2023.101953_bib37","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1016\/S1470-2045(19)30335-3","article-title":"US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017","volume":"20","author":"Fiero","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.101953_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41591-021-01648-4","article-title":"The value of patient-reported outcomes in early-phase clinical trials","volume":"28","author":"Retzer","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.eclinm.2023.101953_bib39","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1038\/s41467-022-33826-4","article-title":"Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection","volume":"13","author":"Aiyegbusi","year":"2022","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.eclinm.2023.101953_bib40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrclinonc.2017.153","article-title":"Patient-reported outcomes in cancer care - hearing the patient voice at greater volume","volume":"14","author":"LeBlanc","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101953_bib41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamaoncol.2019.5566","article-title":"Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials","volume":"6","author":"Atkinson","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.101953_bib42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","article-title":"Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and critical path institute workshop","volume":"21","author":"Kluetz","year":"2018","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.eclinm.2023.101953_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.eclinm.2023.101953_bib44","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/1078-0432.CCR-17-2555","article-title":"Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702300130X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702300130X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:19:20Z","timestamp":1762899560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258953702300130X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":44,"alternative-id":["S258953702300130X"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.101953","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017\u20132022","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.101953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101953"}}